Media 2021
Media 2021
December
Placental cell therapy could deliver new treatment options for liver disease
Associate Professor Rebecca Lim, Mihiri Goonetilleke
Medical Express
Why Invion’s progress towards TNBC treatment can be a game changer
Kalkine Media
3D-bioprinted urogynaecological repair treatment
Dr Kallyanashis Paul, Professor Caroline Gargett, Dr Shayanti Mukherjee
Hospital and healthcare
Insights into Invion’s progress in PhotosoftTM technology for cancer treatment as it gears up for an exciting 2022
Kalkine media
Neural stem cells may hold key to combatting newborn brain injury
News Binding
Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research
Associate Professor Michael Gantier
BusinessWire
Street Insider
Daily Herald Chicago
Biopharma Reporter
November
New hope in lung cancer war
Dr Daniel Gough
Herald Sun
Hobart Mercury
Weekend Gold Coast Bulletin
Medical Xpress
News Binding
How the resented AstraZeneca vaccine could save Australia
Professor Bryan Williams
Daily Mail
Neural stem cells may hold key to combatting newborn brain injury
Today UK News
California News Times
Melbourne scientists have found a way to lessen the side effects of covid-19 vaccines
Professor Michael Gantier
Radio | 3AW
Radio | 5AA
The Australian
Noxopharm (ASX:NOX) signs licensing agreement with Hudson Institute for RNA technology
Professor Michael Gantier
The Market Herald
Proactive Investors
New hope for sick newborns
Professor Suzanne Miller
TV | 9 News
TV | 7 News
Radio | 4BC
Herald Sun
Daily Telegraph
Adelaide Advertiser
Courier Mail
Flicking the inflammation off-switch
Associate Professor Claudia Nold, Professor Marcel Nold
UK Today News
Florida News Times
Medical Express
Pledge Times
October
Study shows Invion’s INV043 could regress triple negative breast cancer tumours
Small caps
Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial
Dr Andrew Stephens
The Market Herald
Hudson CEO appointed to NHMRC Council
Professor Elizabeth Hartland
Hospital Healthcare
Eminetra
Rocks for ROC | a rare ovarian cancer
Radio | ABC Illawarra
Invion has productive quarter following $4.5m capital raise for next-gen photodynamic therapy to treat billion-dollar diseases
Small caps
Noxopharm well-funded to advance “rapidly expanding” clinical program
Proactive Investors
Invion, Dimerix, Orthocell: Promising ASX stocks to watch amid biotech boom
Kalkine Media
Hearts in the right place
Dr Andrew Stephens
CEO Sydney
September
Renowned Scientists Added To Scientific Advisory Group
Dr Minna-Liisa Änkö
Premier of VIC
Hearts in the Right Place: Thian Chew
Dr Andrew Stephens
CEO Magazine
How Do Bats Resist COVID? Insights Could Lead to New Treatments for Humans
Professor Marcel Nold, Associate Professor Claudia Nold
Herald Sun
UKTodayNews
SciTechDaily
California New Times
USA Newsguru
EurekAlert
LeakHerald
Fiercebiotech
Earth
A GP guide to primary aldosteronism
Dr Jun Yang
Australian Doctor Group
Research team lead by Dr Jim Vadolas develops viral gene therapy to treat beta thalassaemia
Dr Jim Vadolas, Dr Tiwa Nualkaew
Neos Kosmos
Invion advances ‘exciting’ photodynamic therapy to treat a range of cancers
Dr Andrew Stephens
Small Caps
Global female scholars award opens for 2022
Dr Shayanti Mukherjee
BiotechDispatch
Can Invion’s promising technology do more than just treat cancer patients?
Dr Andrew Stephens
Kalkline Media
Viruses and the COVID-19 pandemic
Professor Bryan Williams
Radio | 2NUR
August
Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19
Associate Professor Michael Gantier
Street Insider
Galv News
Yahoo Finance
Coffee sellers a sign of pandemic desperation | Covid-19 research
The Australian
Breathing support improves lung function in near-term newborns
Erin McGillick
Today UK News
Invion Group to expand its promising photodynamic therapy technology into new markets
Dr Andrew Stephens
Small Caps
Noxopharm’s Veyonda® may offer other therapeutic opportunities in chronic inflammatory and autoimmune diseases
Professor Michael Gantier
Proactive Investors
Yahoo Finance
July
Geelong MPs questioned on whether they will donate their minimum pay rise to charity
Herald Sun
Geelong Advertiser
Australian biotech submits for approval of world first microbial therapy
News for Business
Medianet
Pharmacy ITK
June
Maria Alexiadis OAM: Part-time scientist, part-time Kumite sensei
Maria Alexiadis
Greek Herald
New drugs may kill and limit reproduction of bowel cancer cells
Associate Professor Ron Firestein
TV | 9 News
Radio | 2GB
InSight+
Photodynamic therapy to reduce tumours
The Pulse
May
Moderna ‘toxic’ vaccine claim a potent dose of misinformation
Dr Bryan Williams
AAP
Monash team co-develop lung disease drug
Associate Professor Michelle Tate
Herald Sun
Geelong Advertiser
Adelaide Advertiser
For International HR day, we’re celebrating HR initiatives that help businesses thrive
Belinda Pelle – HR
HRM – Australian HR Institute News
What 2,000-year-old poo says about our gut bugs
Dr Sam Forster
ABC
Breakthrough discovery for women suffering after traumatic childbirths
Professor Caroline Gargett, Dr Shayanti Mukherjee
TV | 7NEWS
Radio | ABC, 5AA
Herald Sun
Courier Mail
Developing early detection test for Ovarian cancer
Dr Maree Bilandzic
TV | 7NEWS
TV | 10NEWS
Protecting premature babies | discussing an often fatal disease called necrotising enterocolitis (NEC)
Associate Professor Claudia Nold, Professor Marcel Nold
ABC Babytalk podcast
April
Noxopharm’s interim trial data indicates Veyonda® potentially prevents cytokine storm in patients with moderately severe COVID-19
Associate professor Michael Gantier
Proactive
Biotech
March
Australian scientists new world-first sperm discovery
Dr Liza O’Donnell
TV | National Nine News
Radio | ABC Newcastle
Tackling Ovarian Cancer
Associate Professor Ron Firestein
Australian Jewish News
Victorian Women Leading COVID-19 Research Charge
Associate Professor Michelle Tate
Premier of Victoria
Walk For a Worthy Cause
Tegan White, Charmaine Rock, Beth Piscopo
Crandbourne News
February
Ovarian Cancer: Hope on the Horizon
Dr Maree Bilandzic
Tonic magazine
A head start on migraine treatment
The West Australian
January
Noxopharm says study advancing after clinical review
BiotechDispatch